丨证券研究报告丨 公司研究丨点评报告丨蒙娜丽莎（002918.SZ） [Table_Title] 龙头经营承压，意味着价格战已至底部 报告要点 [Table_Summary] 蒙娜丽莎全年实现营业收入 46 亿元，同比下降 22%；归属净利润 1.2 亿元，同比下降 53%， 扣非净利润约 1.0 亿元，同比下降 58%。1 季度实现营业收入 7 亿元，同比下降 16%；归属净 利润-0.6 亿元，同比下降 715%，扣非净利润约-0.7 亿元，同比下降 870%。 分析师及联系人 [Table_Author] 范超 张佩 SAC：S0490513080001 SAC：S0490518080002 SFC：BQK473 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com [Table_Summary2] 事件描述 公司全年实现营业收入 46 亿元，同比下降 22%；归属净利润 1.2 亿元，同比下降 53%，扣非 净利润约 1.0 亿元，同比下降 58%。1 季度实现营业收入 7 亿元，同比下降 16%；归属净利润 -0.6 亿元，同比下降 715%，扣非净利润约-0. ...

Core Viewpoint - The company experienced a decline in revenue for 2024, with a 14% year-on-year decrease, while net profit showed a significant increase of 113% year-on-year, indicating a potential improvement in operational efficiency despite challenging market conditions [1][4]. Group 1: Financial Performance - In 2024, the company achieved revenue of 6.8 billion, a 14% decrease year-on-year, with a net profit of approximately 44 million, reflecting a 113% increase year-on-year [1]. - The first quarter of 2024 saw revenue of 1.4 billion, down 6% year-on-year, and a net profit of 40 million, down 23% year-on-year [1]. - The company's gross margin improved to approximately 21.8% for 2024, up 0.6 percentage points year-on-year, primarily due to stable sales prices and reduced unit costs [3]. Group 2: Market Conditions - The waterproofing industry remains under significant pressure in 2024, with total production of waterproof materials in China declining by 17% year-on-year, and a cumulative decline of 38% compared to the historical peak in 2021 [2]. - The company's main business revenue decreased by 12%, with specific declines in waterproof membrane revenue (15%), waterproof coating revenue (6%), and engineering construction revenue (17%) [2]. Group 3: Strategic Initiatives - The company has implemented a multi-brand distribution strategy targeting different market segments, establishing long-term partnerships with over 3,200 distributors [2]. - In 2024, the company began exploring overseas markets, contributing approximately 2% to total revenue [2]. - Some fundraising projects have been postponed, with the company extending the timeline for certain expansion projects to the end of 2028 due to declining terminal demand and production efficiency improvements [4]. Group 4: Cash Flow and Debt Management - The company's operating cash flow has shown gradual improvement, with a cash collection ratio of 1.08 in the past three years, indicating better revenue structure [3]. - By the end of 2024, accounts receivable and notes amounted to 4.1 billion, slightly down from the end of 2023, while the net cash flow from operating activities was 320 million [3].

科顺股份 20250428 摘要 • 科顺股份 2024 年调整业务结构，主动放弃低毛利和长账期项目，地产和 市政基建收入下降，但海外、B 端、经销及工商项目收入占比提升，整体 毛利率和现金流改善，净利润扭亏为盈至 4,000 多万元，现金流增至 3 亿 多元。 • 2025 年一季度，科顺股份收入降幅收窄至 6%，C 端和海外业务分别增长 30%和 60%，毛利率达近两年较高水平 24.几，现金流大幅改善至负 3 亿 多元。公司计划民建保持 40%高增长，公建经销实现正增长，直销稳中略 增，市政基建严格风控。 • 科顺股份海外市场虽基数小，但增长迅速，2024 年增长 60%至 2.7 亿元。 董事长直接管理海外业务，加强人员配置、市场推广和产品投放。2025 年计划在东南亚设产能，与当地伙伴合资，预计海外市场增长接近 80%。 • 工程板块中，工商类项目毛利率最高，地产项目次之，市政项目毛利率最 低且账期长。2025 年一季度毛利率改善主要归因于收入和产品结构优化， 沥青降价预计二季度显现成本优势，沥青价格每下降 10%可提升毛利率约 2.2~2.3 个百分点。 Q&A 请介绍科顺股份 2024 年年报及 ...

Core Viewpoint - Zontai Automobile reported a significant decline in financial performance for 2024, with a sales revenue of 558 million yuan, down 23.96% year-on-year, and a net loss attributable to shareholders of 1 billion yuan, an increase in loss of 6.82% compared to the previous year [1][2] Financial Performance - Total assets at the end of 2024 were 3.606 billion yuan, a decrease of 41.64% from the end of 2023 [2][9] - Net assets attributable to shareholders were 234 million yuan, down 80.98% from the end of 2023 [2][9] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -1.469 billion yuan, a year-on-year increase in loss of 49.28% [1][2] - The basic and diluted earnings per share were both -0.20 yuan, a decrease of 5.26% from the previous year [2] Sales and Production - The total vehicle sales for 2024 were only 14 units, a dramatic drop of 98.74% year-on-year, with no vehicles produced during the year [3][4] - The inventory at the end of 2024 was 336 units, slightly down from 350 units in the previous year [4] - The company’s revenue primarily came from automotive parts and door sales, with vehicle sales contributing minimally to total revenue [3] Management and Corporate Governance - Despite ongoing losses, the total annual compensation for the board of directors and senior management was 9.5491 million yuan, with the chairman and vice president receiving significant salaries [1][3] - Frequent changes in senior management have been noted, with several executives resigning for personal reasons, which may be linked to the company's poor performance [4][5] Industry Context - Zontai Automobile has faced continuous losses since 2019, with a significant decline in sales from over 300,000 units in 2016 and 2017 to just 14 units in 2024 [5][7] - The company has struggled to recover from a financial crisis that began in 2020, leading to a halt in production until 2022 [7][9] - The company plans to enhance its product development and production capabilities, particularly focusing on the T300 model for future growth [9]

Core Viewpoint - The performance of several vaccine companies in China is significantly declining in 2024 due to industry policy adjustments, decreased public willingness to vaccinate, and changing market demands, leading to a challenging environment for the industry [1] Financial Performance - The average revenue of vaccine companies in 2024 is 7.131 billion yuan, down 21.63% from 9.099 billion yuan in 2023, while the average net profit is 788 million yuan, a decrease of 35.60% from 1.222 billion yuan in 2023 [1] - Companies like Zhifei Biological, Wantai Biological, and Hualan Biological reported revenue declines exceeding 50%, while Watson Biological, Baike Biological, and Jindike saw declines of over 30% [1] - Kangxino's revenue increased by over 130% due to its quadrivalent meningococcal conjugate vaccine, benefiting from the resolution of global public health events [1] Price Competition Impact - The price war among vaccine products, particularly HPV, influenza, and pneumonia vaccines, has severely impacted net profits, with Wantai Biological, Kangtai Biological, Hualan Biological, and Zhifei Biological experiencing declines of 91.49%, 76.59%, 76.10%, and 74.99% respectively [2] - Wantai Biological's revenue for 2024 is 2.245 billion yuan, down 59.25%, and its net profit is 106 million yuan, down 91.49% [6] - Watson Biological's revenue is 2.821 billion yuan, a decline of 31.41%, with a net profit of 142 million yuan, down 66.10% [6] Market Dynamics - The domestic vaccine market is becoming increasingly competitive, with many companies focusing on traditional products and facing challenges from product homogeneity and market saturation [3] - The overall vaccination rate in China is low, with only about 3% for influenza vaccines, indicating significant growth potential in the market despite current pressures [7] R&D and Innovation - Companies are increasing R&D investments, with Zhifei Biological investing 1.391 billion yuan in 2024, and several companies allocating over 20% of their revenue to R&D [8] - New vaccine technologies, including mRNA and DNA vaccines, are emerging, which could lead to breakthroughs in disease prevention and treatment [9] International Expansion - Many vaccine companies are pursuing international markets, with Kangxino and Baike Biological successfully exporting products to various countries [10][11] - Watson Biological reported overseas revenue of 570 million yuan in 2024, a year-on-year increase of approximately 98% [11] - The global human vaccine market is projected to grow significantly, with emerging markets providing opportunities for Chinese vaccine companies due to their competitive pricing [12][13]

丨证券研究报告丨 公司研究丨点评报告丨科顺股份（300737.SZ） [Table_Title] 下滑收敛，经营优化 报告要点 范超 张佩 SAC：S0490513080001 SAC：S0490518080002 SFC：BQK473 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_Summary] 科顺股份 2024 年实现收入 68 亿元，同比下降 14%，归属净利润约 0.44 亿元，同比增长 113%， 扣非净利润约-2.5 亿元。1 季度实现营业收入 14 亿元，同比下降 6%，归属净利润 0.4 亿元， 同比下降 23%，扣非净利润约 0.2 亿元，同比下降 4%。 分析师及联系人 [Table_Author] 1、地产行业需求低预期； 2、原材料价格继续上涨。 丨证券研究报告丨 2025-04-28 公司研究丨点评报告 科顺股份（300737.SZ） cjzqdt11111 [Table_Title2] 下滑收敛，经营优化 [Table_Summary2] 事件描述 公司 2024 年实现收入 68 亿元，同比下降 14%，归属净利 ...

以下文章来源于36氪未来消费 ，作者钟艺璇 36氪未来消费 . 在这里看到消费的未来。36氪旗下官方账号。 一杯京东3.9元的生椰拿铁，到库迪加盟商手上，究竟能到手多少钱？ 文 ｜ 钟艺璇 编辑 ｜ 乔芊 来源｜ 36氪未来消费（ID：lslb168） 封面来源 ｜ 品牌官网 外卖平台大战还在硝烟四起，但第一批受益者已经出现——库迪加盟商。 早在京东外卖补贴的号角吹响前，平台发券补贴的行为已经默默开始，高频率、低决策成本的茶饮咖啡品类向来是外卖补贴的第 一战场，这次轮到了库迪。一位北京库迪加盟商陈星注意到，自己的京东订单在3月中旬开始，突然出现了第一个峰值，此后带动 总销量一路上扬。 这也意味着，对于加盟商们来说，京东这场掀起的外卖补贴，真正利好的不是单杯毛利，而是销量的提升。 作为一个从诞生以来就固定9块9，定价贴地飞行的咖啡品牌，门店销量和运营支出一直是库迪加盟商们最重要的两个利润考核指 标。"总体来看，就算单杯毛利没上去，单量多的话，原材料损耗也就降低了，反过来利润也能提升"，前述加盟商说。 但一些加盟商也表达了不同的想法。陈星告诉36氪，从长期来看，加盟商收入还得靠到店订单，目前自己的到店订单补贴线在 ...

Core Viewpoint - 2024 is projected to be the most challenging year in the past decade for the industry, with significant difficulties anticipated for small and medium enterprises [1][99]. Group 1: Industry Overview - The consensus among entrepreneurs is that 2024 will be particularly tough, with many small businesses struggling to survive [2][99]. - Approximately 90% of small and medium enterprises in China do not survive beyond three years, highlighting the challenges faced by new businesses [4]. Group 2: Market Dynamics - The pet food industry has a compound annual growth rate (CAGR) that ranks second among consumer goods, indicating substantial growth potential as pet ownership increases in China [17]. - The industry concentration ratio (CR10) for the pet food sector was only 24% in 2022, suggesting a relatively low level of market maturity compared to other sectors like infant formula, which has a CR10 of 70% [20][19]. - The best entry window for new players in the pet food market was identified as 2017-2021, with 2021 being the last optimal time for non-resource-based entrepreneurs to enter [23]. Group 3: Business Challenges - The COVID-19 pandemic significantly impacted business operations, with supply chain disruptions and cash flow issues arising from lockdowns [36][37]. - The company faced challenges in logistics and inventory management during the pandemic, leading to a need for adaptive strategies [40]. Group 4: Product Development and Strategy - The company focuses on high-quality, functional pet food products, emphasizing transparency in ingredient sourcing and quality control [53][56]. - The development of a weight management cat food product was driven by a commitment to pet health, despite market trends favoring weight gain products [58]. Group 5: Marketing and Customer Acquisition - The company has relied on guerrilla marketing tactics to acquire customers, particularly through social media platforms like Douyin and Xiaohongshu [63][71]. - The shift in platform dynamics, particularly on Douyin, has necessitated a reevaluation of marketing strategies, with a focus on building relationships with pet influencers [73]. Group 6: Financial Performance and Future Outlook - The cost of acquiring new customers has doubled from 2022 to 2024, indicating increased competition and market pressures [62]. - The company has maintained a break-even point early in its operations, but this cautious approach may have limited growth opportunities during a critical market expansion phase [92].

Core Viewpoint - JinkoSolar, a leading company in the photovoltaic industry, reported a significant loss for the first time since returning to the A-share market in 2019, with a net loss of 4.66 billion yuan in 2024, marking a 166% decrease compared to a profit of 7.04 billion yuan in 2023 [1][3]. Financial Performance - In 2024, JinkoSolar achieved a revenue of 70.121 billion yuan, a year-on-year decline of 14% [1]. - The company experienced a massive quarterly loss of 4.17 billion yuan in Q4 2024, primarily due to asset impairment losses, which accounted for 71.49% of the total net loss [3]. - The gross margin in the domestic market plummeted by 20.09 percentage points to -7.98%, while in Europe, it fell by 17.19 percentage points to -3.51% [3]. - Despite a gross margin of 31.43% in the Americas, which is the highest among all regions, it still saw a decline of 4.63 percentage points [3]. Dividend Policy - Due to the financial losses, JinkoSolar announced it would not distribute cash dividends, issue bonus shares, or increase share capital from reserves [4]. Market Conditions - The global photovoltaic component market is facing severe overcapacity, with prices dropping to as low as 0.65 yuan/W, impacting the profitability of many manufacturers, including JinkoSolar, which saw its gross margin decrease by 12.96 percentage points to 4.82% [6]. - JinkoSolar's total shipment volume reached 79.447 GW in 2024, with overseas shipments accounting for approximately 49% [6]. R&D and Capacity Expansion - In 2024, JinkoSolar invested 3.711 billion yuan in R&D, representing 5.29% of its revenue, and holds 1,899 effective patents, including 1,031 invention patents [7]. - The company is accelerating its overseas capacity expansion, including a project in Oman with an annual capacity of 6 GW for batteries and 3 GW for components [7]. Management Changes - JinkoSolar experienced a management change with the resignation of its Vice President and Board Secretary, Wu Tingdong, and the appointment of Qin Shilong as his successor [8]. - Industry insiders suggest that frequent executive departures may be related to succession planning within the company [9].

Group 1: Financial Performance - In 2024, the company achieved a revenue of 23.58 billion yuan, a year-on-year increase of 60.87% in the smart toilet and cover category, which accounted for 13.37% of total revenue [3] - The first quarter of 2025 saw a revenue decline of approximately 21% year-on-year, primarily due to changes in trade policies and varying regional consumer promotion policies [3] - The company's net profit margin improved in the fourth quarter of 2024, influenced by exchange rate fluctuations and a recovery in sales performance [4] Group 2: Market and Policy Impact - The company's direct exports to North America account for 10%-15% of overseas revenue, which is a small portion of total revenue [5] - The implementation of national subsidy policies has positively impacted consumer behavior in home improvement, enhancing the penetration rate of smart toilets [4] - The upcoming new national standards for toilets and mandatory product certification are expected to raise market entry barriers, benefiting companies with strong R&D capabilities [6][7] Group 3: Future Outlook and Strategy - For 2025, the company projects a revenue growth of 10% and a net profit growth of 9.20%, with significant investments in brand building and marketing [7] - The focus for future product development will be on upgrading existing features, emphasizing health, environmental sustainability, and hygiene [7] - The company aims to diversify its market channels and enhance its product matrix, including smart toilets, drainage products, and wellness products [7]